Business Context and Reporting Period
Company: Predictive Oncology Inc. (POAI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A knowledge-driven company applying AI to oncology drug discovery using a proprietary biobank of 150,000+ tumor samples. Operations are divided into three segments: Pittsburgh (AI/3D models), Birmingham (biologics solubility/stability), and Eagan (STREAMWAY medical fluid waste management systems).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $278,722 | $698,368 | $730,005 |
| Gross Profit | $125,754 | $357,985 | $450,105 |
| Gross Margin | 45.1% | 51.3% | 61.7% |
| Net Loss | $(3,181,261) | $(7,400,104) | $(7,345,170) |
| Loss Per Share (Basic/Diluted) | $(0.68) | $(1.70) | $(1.84) |
| Cash and Equivalents (End of Period) | $5,331,770 (as of June 30, 2024) | ||
| Operating Cash Flow (YTD) | $(6,634,072) used | ||
| Total Debt (Current Note Payable) | $276,932 | ||
| Accumulated Deficit | $(175,161,987) |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2024 revenue decreased 43% compared to Q2 2023 ($278k vs. $490k), primarily due to a change in sales mix with decreased sales of STREAMWAY systems. YTD revenue decreased slightly by 4% ($698k vs. $730k) due to lower biologics sales in the Birmingham segment.
- Margin Compression: Gross margin declined from 67% in Q2 2023 to 45% in Q2 2024, attributed to increased labor costs and the shift in sales mix.
- Expense Reduction: General and Administrative (G&A) expenses decreased by $567k in Q2 2024 compared to the prior year, driven by reduced employee compensation and investor relations costs. However, Sales and Marketing expenses increased YTD by $225k due to severance costs for a former executive.
- Capital Raise: The company completed an At-The-Market (ATM) offering in May 2024, selling 1.6 million shares for gross proceeds of approximately $3.7 million, providing net cash from financing activities of $3.25 million YTD.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. The company has an accumulated deficit of $175 million and requires significant additional capital to meet operating needs.
- Cost Savings Initiative: On July 25, 2024, the Board approved a strategic cost savings plan to consolidate the Birmingham laboratory operations into the Pittsburgh facility. Implementation began in August 2024, with an expected 20% reduction in the annual cash burn rate upon full implementation in Q4 2024.
- Subsequent Financing: In late July 2024, the company executed a warrant inducement transaction, raising approximately $1.26 million by allowing holders to exercise warrants at a reduced price of $1.32 per share.
- Risks: Key risks include the inability to secure future financing on acceptable terms, potential dilution to shareholders, and the failure to achieve profitability in the near term. The company relies heavily on external funding as operating revenues are insufficient to sustain operations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $5.3 million cash balance against the $6.6 million operating cash burn rate for the first half of the year.
- Cost Reduction Efficacy: Monitor the progress of the Birmingham-to-Pittsburgh consolidation to confirm the projected 20% reduction in operating cash usage.
- Revenue Concentration: Note that a single customer represented 34% of total revenue for the six months ended June 30, 2024.
- Dilution Impact: Assess the impact of the recent ATM offering and warrant inducement transaction on existing shareholder equity.
- Debt Obligations: Review the terms of the $277k note payable for D&O insurance and the $2.4 million in operating lease liabilities.